In all, our study provides new insights into the mechanisms by which IRE1α inhibition protects against obesity and insulin resistance and serves as a foundation for targeting IRE1α as a therapeutic means in the treatment of obesity and insulin resistance. This evidence concerns the gene ERN1 and obesity due to melanocortin 4 receptor deficiency.